6 days ago · Leerink upgraded Regeneron to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to capitalize ...

4 days ago · REGN stock opened at $710.00 on Wednesday. Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform.

6 days ago · Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday.

6 days ago · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals from Market Perform to Outperform.. What is the Fund Sentiment? There are 2,472 funds ...

5 days ago · Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by investment analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating in a report issued on Wednesday, Zacks.com reports. A number of other equities research analysts also recently weighed in on the company.

Jan 28, 2025 · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform.

6 days ago · Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $959.83, according to analysts polled by FactSet. ...

Jan 28, 2025 · On Tuesday, Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ: REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating.

Jan 28, 2025 · Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on May 2, 2024. Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $1,013.65, according to analysts polled by FactSet. ...